dc.creator | Sampaio-Barros P.D. | |
dc.creator | Zimmermann A.F. | |
dc.creator | Muller C.S. | |
dc.creator | Borges C.T.L. | |
dc.creator | Freire E.A.M. | |
dc.creator | Maretti G.B. | |
dc.creator | Neto J.F.M. | |
dc.creator | Salgado M.C.F. | |
dc.creator | da Cunha Sauma M.F.L. | |
dc.creator | de Azevedo M.N.L. | |
dc.creator | Fontenelle S. | |
dc.creator | Kayser C. | |
dc.date | 2013 | |
dc.date | 2015-06-25T19:14:06Z | |
dc.date | 2015-11-26T15:11:53Z | |
dc.date | 2015-06-25T19:14:06Z | |
dc.date | 2015-11-26T15:11:53Z | |
dc.date.accessioned | 2018-03-28T22:21:59Z | |
dc.date.available | 2018-03-28T22:21:59Z | |
dc.identifier | | |
dc.identifier | Revista Brasileira De Reumatologia. , v. 53, n. 3, p. 258 - 275, 2013. | |
dc.identifier | | |
dc.identifier | 10.1590/S0482-50042013000300004 | |
dc.identifier | http://www.scopus.com/inward/record.url?eid=2-s2.0-84884953100&partnerID=40&md5=6de4ec43ab30bde4ac045cbb91322f37 | |
dc.identifier | http://www.repositorio.unicamp.br/handle/REPOSIP/89027 | |
dc.identifier | http://repositorio.unicamp.br/jspui/handle/REPOSIP/89027 | |
dc.identifier | 2-s2.0-84884953100 | |
dc.identifier.uri | http://repositorioslatinoamericanos.uchile.cl/handle/2250/1258250 | |
dc.description | [No abstract available] | |
dc.description | 53 | |
dc.description | 3 | |
dc.description | 258 | |
dc.description | 275 | |
dc.description | Johnson, S.R., Feldman, B.M., Hawker, G.A., Classification criteria for systemic sclerosis subsets (2007) J Rheumatol, 34, pp. 1855-1863 | |
dc.description | Masi, A.T., Rodnan, G.P., Medsger Jr., T.A., Altman, R.D., D'Angelo, W.A., Fries, J.F., Preliminary criteria for the classification of systemic sclerosis (scleroderma) (1980) Arthritis Rheum, 23, pp. 581-590 | |
dc.description | LeRoy, E.C., Black, C., Fleischmajer, R., Jablonska, S., Krieg, T., Medsger Jr., T.A., Scleroderma (systemic sclerosis): classification, subsets and pathogenesis (1988) J Rheumatol, 15, pp. 202-205 | |
dc.description | Walker, J.G., Pope, J., Baron, M., Leclercq, S., Hudson, M., Taillefer, S., The development of systemic sclerosis classification criteria (2007) Clin Rheumatol, 26, pp. 1401-1409 | |
dc.description | Walker, U.A., Tyndall, A., Czirjak, L., Denton, C., Farge-Bancel, D., Kowal-Bielecka, O., Clinical risk assessment of organ manifestations in systemic sclerosis - a report from the EULAR Scleroderma Trials And Research (EUSTAR) group data base (2007) Ann Rheum Dis, 66, pp. 754-763 | |
dc.description | LeRoy, E.C., Medsger Jr., T.A., Criteria for the classification of early systemic sclerosis (2001) J Rheumatol, 28, pp. 1573-1576 | |
dc.description | Poormoghim, H., Lucas, M., Fertig, N., Medsger Jr., T.A., Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients (2000) Arthritis Rheum, 43, pp. 444-451 | |
dc.description | Avouac, J., Fransen, J., Walker, U.A., Riccieri, V., Smith, V., Muller, C., Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group (2011) Ann Rheum Dis, 70, pp. 476-481 | |
dc.description | Pavlov-Dolijanovic, S., Damjanov, N.S., Stojanovic, R.M., Vujasinovictupar, N.Z., Stanisavljevic, D.M., Scleroderma pattern of nailfold capillary changes as predictive value for the development of a connective tissue disease: a follow-up study of 3,029 patients with primary Raynaud's phenomenon (2012) Rheumatol Int, 32, pp. 3039-3045 | |
dc.description | McGill, N.W., Gow, P.J., Nailfold capillaroscopy: a blinded study of its discriminatory value in scleroderma, systemic lupus erythematosus, and rheumatoid arthritis (1986) Aust N Z J Med, 16, pp. 457-460 | |
dc.description | Ingegnoli, F., Boracchi, P., Gualtierotti, R., Biganzoli, E.M., Zeni, S., Lubatti, C., Fantini, F., Improving outcome prediction of systemic sclerosis from isolated Raynaud's phenomenon: role of autoantibodies and nailfold capillaroscopy (2010) Rheumatology (Oxford), 49, pp. 797-805 | |
dc.description | Cutolo, M., Sulli, A., Pizzorni, C., Accardo, S., Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis (2000) J Rheumatol, 27, pp. 155-160 | |
dc.description | Wildt, M., Wuttge, D.M., Hesselstrand, R., Scheja, A., Assessment of capillary density in systemic sclerosis with three different capillaroscopic methods (2012) Clin Exp Rheumatol, 30 (2 SUPPL. 71), pp. S50-S54 | |
dc.description | Muroi, E., Hara, T., Yanaba, K., Ogawa, F., Yoshizaki, A., Takenaka, M., Shimizu, K., Sato, S., A portable dermatoscope for easy, rapid examination of periungueal nailfold capillary changes in patients with systemic sclerosis (2011) Rheumatol Int, 31, pp. 1601-1606 | |
dc.description | Sebastiani, M., Manfredi, A., Colaci, M., D'Amico, R., Malagoli, V., Giuggioli, D., Ferri, C., Capillaroscopic skin ulcer risk index: a new prognostic tool for digital skin ulcer development in systemic sclerosis patients (2009) Arthritis Rheum, 61 (5), pp. 688-694 | |
dc.description | Sebastiani, M., Manfredi, A., Vukatana, G., Moscatelli, S., Riato, L., Bocci, M., Predictive role of capillaroscopic skin ulcer risk index in systemic sclerosis: a multicentre validation study (2012) Ann Rheum Dis, 71, pp. 67-70 | |
dc.description | Bredemeier, M., Xavier, R.M., Capobianco, K.G., Restelli, V.G., Rohde, L.E., Pinotti, A.F., Nailfold capillary microscopy can suggest pulmonary disease activity in systemic sclerosis (2004) J Rheumatol, 31, pp. 286-294 | |
dc.description | Joyal, F., Choquette, D., Roussin, A., Levington, C., Senécal, J.L., Evaluation of the severity of systemic sclerosis by nailfold capillary microscopy in 112 patients (1992) Angiology, 43 (3 PART 1), pp. 203-210 | |
dc.description | Riboldi, P., Asero, R., Origgi, L., Crespi, S., Meroni, P.L., Sguotti, C., Sabbadini, M.G., Antinuclear antibodies in progressive systemic sclerosis (1985) Clin Exp Rheumatol, 3, pp. 205-211 | |
dc.description | Kipnis, R.J., Craft, J., Hardin, J.A., The analysis of antinuclear and antinucleolar autoantibodies of scleroderma by radioimmunoprecipitation assays (1990) Arthritis Rheum, 33, pp. 1431-1437 | |
dc.description | Simeón-Aznar, C.P., Fonollosa-Plá, V., Tolosa-Vilella, C., Espinosa-Garriga, G., Ramos-Casals, M., Campillo-Grau, M., Registry of the Spanish Network for Systemic Sclerosis: Clinical pattern according to cutaneous subsets and immunological status (2012) Semin Arthritis Rheum, 41, pp. 789-800 | |
dc.description | Hunzelmann, N., Genth, E., Krieg, T., Lehmacher, W., Melchers, I., Meurer, M., Registry of the German Network for Systemic Scleroderma: The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement (2008) Rheumatology (Oxford), 47, pp. 1185-1192 | |
dc.description | Aeschlimann, A., Meyer, O., Bourgeois, P., Haim, T., Belmatoug, N., Palazzo, E., Kahn, M.F., Anti-Scl-70 antibodies detected by immunoblotting in progressive systemic sclerosis: specificity and clinical correlations (1989) Ann Rheum Dis, 48, pp. 992-997 | |
dc.description | Harvey, G.R., Butts, S., Rands, A.L., Patel, Y., McHugh, N.J., Clinical and serological associations with anti-RNA polymerase antibodies in systemic sclerosis (1999) Clin Exp Immunol, 117, pp. 395-402 | |
dc.description | Tan, F.K., Arnett, F.C., Reveille, J.D., Ahn, C., Antohi, S., Sasaki, T., Nishi Bona, C.A., Autoantibodies to fibrillin 1 in systemic sclerosis: ethnic differences in antigen recognition and lack of correlation with specific clinical features or HLA alleles (2000) Arthritis Rheum, 43, pp. 2464-2471 | |
dc.description | Tan, F.K., Arnett, F.C., Antohi, S., Saito, S., Mirarchi, A., Spiera, H., Autoantibodies to the extracellular matrix microfibrillar protein, fibrillin-1, in patients with scleroderma and other connective tissue diseases (1999) J Immunol, 163, pp. 1066-1072 | |
dc.description | Steen, V.D., Autoantibodies in systemic sclerosis (2005) Semin Arthritis Rheum, 35, pp. 35-42 | |
dc.description | Walker, J.G., Fritzler, M.J., Update on autoantibodies on systemic sclerosis (2007) Curr Opin Rheumatol, 19, pp. 580-591 | |
dc.description | Kaldas, M., Khanna, P.P., Furst, D.E., Clements, P.J., Wong, W.K., Seibold, J.R., Sensitivity to change of the modified Rodnan skin score in diffuse systemic sclerosis--assessment of individual body sites in two large randomized controlled trials (2009) Rheumatology (Oxford), 48, pp. 1143-1146 | |
dc.description | Merkel, P.A., Silliman, N.P., Denton, C.P., Furst, D.E., Khanna, D., Emery, P., Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial (2008) Arthritis Rheum, 59, pp. 699-705 | |
dc.description | van den Hoogen, F.H., Boerbooms, A.M., Swaak, A.J., Rasker, J.J., van Lier, H.J., van de Putte, L.B., Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial (1996) Br J Rheumatol, 35, pp. 364-372 | |
dc.description | Pope, J.E., Bellamy, N., Seibold, J.R., Baron, M., Ellman, M., Carette, S., A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma (2001) Arthritis Rheum, 44, pp. 1351-1358 | |
dc.description | Clements, P.J., Furst, D.E., Wong, W.K., Mayes, M., White, B., Wigley, F., High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial (1999) Arthritis Rheum, 42, pp. 1194-1203 | |
dc.description | Seibold, J.R., Korn, J.H., Simms, R., Clements, P.J., Moreland, L.W., Mayes, M.D., Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial (2000) Ann Intern Med, 132, pp. 871-879 | |
dc.description | Khanna, D., Clements, P.J., Furst, D.E., Korn, J.H., Ellman, M., Rothfield, N., Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebocontrolled trial (2009) Arthritis Rheum, 60, pp. 1102-1111 | |
dc.description | Postlethwaite, A.E., Wong, W.K., Clements, P., Chatterjee, S., Fessler, B.J., Kang, A.H., A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease (2008) Arthritis Rheum, 58, pp. 1810-1822 | |
dc.description | Kawald, A., Burmester, G.R., Huscher, D., Sunderkötter, C., Riemekasten, G., Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study (2008) J Rheumatol, 35, pp. 1830-1837 | |
dc.description | Tashkin, D.P., Elashoff, R., Clements, P.J., Goldin, J., Roth, M.D., Furst, D.E., Cyclophosphamide versus placebo in scleroderma lung disease (2006) N Engl J Med, 354, pp. 2655-2666 | |
dc.description | Clements, P.J., Roth, M.D., Elashoff, R., Tashkin, D.P., Goldin, J., Silver, R.M., Scleroderma lung study (SLS): differences in presentation and course of patients with limited versus diffuse systemic sclerosis (2007) Ann Rheum Dis, 66, pp. 1641-1647 | |
dc.description | Mendoza, F.A., Nagle, S.J., Lee, J.B., Jimenez, S.A., A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset (2012) J Rheumatol, 39, pp. 1241-1247 | |
dc.description | Daoussis, D., Liossis, S.N., Tsamandas, A.C., Kalogeropoulou, C., Kazantzi, A., Sirinian, C., Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study (2010) Rheumatology (Oxford), 49, pp. 271-280 | |
dc.description | Daoussis, D., Liossis, S.N., Tsamandas, A.C., Kalogeropoulou, C., Paliogianni, F., Sirinian, C., Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis (2012) Clin Exp Rheumatol, 30 (2 SUPPL. 71), pp. S17-S22 | |
dc.description | Spiera, R.F., Gordon, J.K., Mersten, J.N., Magro, C.M., Mehta, M., Wildman, H.F., Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial (2011) Ann Rheum Dis, 70, pp. 1006-1009 | |
dc.description | Khanna, D., Saggar, R., Mayes, M.D., Abtin, F., Clements, P.J., Maranian, P., A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease (2011) Arthritis Rheum, 63, pp. 3540-3546 | |
dc.description | Berger, R.G., Featherstone, G.L., Raasch, R.H., McCartney, W.H., Hadler, N.M., Treatment of calcinosis universalis with lowdose warfarin (1987) Am J Med, 83, pp. 72-76 | |
dc.description | Yoshida, S., Torikai, K., The effects of warfarin on calcinosis in a patient with systemic sclerosis (1993) J Rheumatol, 20, pp. 1233-1235 | |
dc.description | Cukierman, T., Elinav, E., Korem, M., Chajek-Shaul, T., Low dose warfarin treatment for calcinosis in patients with systemic sclerosis (2004) Ann Rheum Dis, 63, pp. 1341-1343 | |
dc.description | Lassoued, K., Saiag, P., Anglade, M.C., Roujeau, J.C., Touraine, R.L., Failure of warfarin in treatment of calcinosis universalis (1988) Am J Med, 84, pp. 795-796 | |
dc.description | Palmieri, G.M., Sebes, J.I., Aelion, J.A., Moinuddin, M., Ray, M.W., Wood, G.C., Treatment of calcinosis with diltiazem (1995) Arthritis Rheum, 38, pp. 1646-1654 | |
dc.description | Vayssairat, M., Hidouche, D., Abdoucheli-Baudot, N., Gaitz, J.P., Clinical significance of subcutaneous calcinosis in patients with systemic sclerosis. Does diltiazem induce its regression? (1998) Ann Rheum Dis, 57, pp. 252-254 | |
dc.description | Robertson, L.P., Marshall, R.W., Hickling, P., Treatment of cutaneous calcinosis in limited systemic sclerosis with minocycline (2003) Ann Rheum Dis, 62, pp. 267-269 | |
dc.description | Fuchs, D., Fruchter, L., Fishel, B., Holtzman, M., Yaron, M., Colchicine suppression of local inflammation due to calcinosis in dermatomyositis and progressive systemic sclerosis (1986) Clin Rheumatol, 5, pp. 527-530 | |
dc.description | Daoussis, D., Antonopoulos, I., Liossis, S.N., Yiannopoulos, G., Andonopoulos, A.P., Treatment of systemic sclerosisassociated calcinosis: A case report of rituximab-induced regression of CREST-related calcinosis and review of the literature (2012) Semin Arthritis Rheum, 41, pp. 822-829 | |
dc.description | Saddic, N., Miller, J.J., Miller 3rd, O.F., Clarke, J.T., Surgical debridement of painful fingertip calcinosis cutis in CREST syndrome (2009) Arch Dermatol, 145, pp. 212-213 | |
dc.description | Bottomley, W.W., Goodfield, M.J., Sheehan-Dare, R.A., Digital calcification in systemic sclerosis: effective treatment with good tissue preservation using the carbon dioxide laser (1996) Br J Dermatol, 135, pp. 302-304 | |
dc.description | Sparsa, A., Lesaux, N., Kessler, E., Bonnetblanc, J.M., Blaise, S., Lebrun-Ly, V., Treatment of cutaneous calcinosis in CREST syndrome by extracorporeal shock wave lithotripsy (2005) J Am Acad Dermatol, 53 (5 SUPPL. 1), pp. S263-S265 | |
dc.description | Thompson, A.E., Shea, B., Welch, V., Fenlon, D., Pope, J.E., Calciumchannel blockers for Raynaud's phenomenon in systemic sclerosis (2001) Arthritis Rheum, 44, pp. 1841-1847 | |
dc.description | Kahan, A., Amor, B., Menkès, C.J., Weber, S., Guérin, F., Degeorges, M., Nicardipine in the treatment of Raynaud's phenomenon: a randomized double-blind trial (1987) Angiology, 38, pp. 333-337 | |
dc.description | Kahan, A., Amor, B., Menkes, C.J., A randomised doubleblind trial of diltiazem in the treatment of Raynaud's phenomenon (1985) Ann Rheum Dis, 44, pp. 30-33 | |
dc.description | Hummers, L.K., Wigley, F.M., Management of Raynaud's phenomenon and digital ischemic lesions in scleroderma (2003) Rheum Dis Clin North Am, 29, pp. 293-313 | |
dc.description | Wigley, F.M., Wise, R.A., Seibold, J.R., McCloskey, D.A., Kujala, G., Medsger Jr., T.A., Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis.A multicenter, placebo-controlled, double-blind study (1994) Ann Intern Med, 120, pp. 199-206 | |
dc.description | Wigley, F.M., Korn, J.H., Csuka, M.E., Medsger Jr., T.A., Rothfield, N.F., Ellman, M., Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study (1998) Arthritis Rheum, 41, pp. 670-677 | |
dc.description | Scorza, R., Caronni, M., Mascagni, B., Berruti, V., Bazzi, S., Micallef, E., Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study (2001) Clin Exp Rheumatol, 19, pp. 503-508 | |
dc.description | Rademaker, M., Cooke, E.D., Almond, N.E., Beacham, J.A., Smith, R.E., Mant, T.G., Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study (1989) BMJ, 298, pp. 561-564 | |
dc.description | Pope, J., Fenlon, D., Thompson, A., Shea, B., Furst, D., Wells, G., Prazosin for Raynaud's phenomenon in progressive systemic sclerosis (2000) Cochrane Database Syst Rev, (2). , CD000956 | |
dc.description | Surwit, R.S., Gilgor, R.S., Allen, L.M., Duvic, M., A doubleblind study of prazosin in the treatment of Raynaud's phenomenon in scleroderma (1984) Arch Dermatol, 120, pp. 329-331 | |
dc.description | Nguyen, V.A., Eisendle, K., Gruber, I., Hugl, B., Reider, D., Reider, N., Effect of the dual endothelin receptor antagonist bosentan on Raynaud's phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study (2010) Rheumatology (Oxford), 49, pp. 583-587 | |
dc.description | Gliddon, A.E., Doré, C.J., Black, C.M., McHugh, N., Moots, R., Denton, C.P., Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril (2007) Arthritis Rheum, 56, pp. 3837-3846 | |
dc.description | Dziadzio, M., Denton, C.P., Smith, R., Howell, K., Blann, A., Bowers, E., Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteenweek, randomized, parallel-group, controlled trial (1999) Arthritis Rheum, 42, pp. 2646-2655 | |
dc.description | Shenoy, P.D., Kumar, S., Jha, L.K., Choudhary, S.K., Singh, U., Misra, R., Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a doubleblind randomized cross-over trial (2010) Rheumatology (Oxford), 49, pp. 2420-2428 | |
dc.description | Schiopu, E., Hsu, V.M., Impens, A.J., Rothman, J.A., McCloskey, D.A., Wilson, J.E., Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis (2009) J Rheumatol, 36, pp. 2264-2268 | |
dc.description | De La Veja, A.J., Derk, C.T., Phosphodiesterase-5 inhibitors for the treatment of Raynaud's: a novel indication (2009) Expert Opin Invest Drugs, 18, pp. 23-29 | |
dc.description | Herrick, A.L., van den Hoogen, F., Gabrielli, A., Tamimi, N., Reid, C., O'Connell, D., Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis (2011) Arthritis Rheum, 63, pp. 775-782 | |
dc.description | Pope, J., Fenlon, D., Thompson, A., Shea, B., Furst, D., Wells, G., Silman, A., Cyclofenil for Raynaud's phenomenon in progressive systemic sclerosis (2000) Cochrane Database Syst Rev, (2). , CD000955 | |
dc.description | Lukác, J., Rovenskỳ, J., Tauchmannová, H., Zitnan, D., Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial (1985) Drugs Exp Clin Res, 11, pp. 659-663 | |
dc.description | Abou-Raya, A., Abou-Raya, S., Helmii, M., Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers (2008) J Rheumatol, 35, pp. 1801-1808 | |
dc.description | Herrick, A.L., Hollis, S., Schofield, D., Rieley, F., Blann, A., Griffin, K., A double-blind placebo-controlled trial of antioxidant therapy in limited cutaneous systemic sclerosis (2000) Clin Exp Rheumatol, 18, pp. 349-356 | |
dc.description | Wigley, F.M., Seibold, J.R., Wise, R.A., McCloskey, D.A., Dole, W.P., Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis (1992) J Rheumatol, 19 (9), pp. 1407-1414 | |
dc.description | Langevitz, P., Buskila, D., Lee, P., Urowitz, M.B., Treatment of refractory ischemic skin ulcers in patients with Raynaud's phenomenon with PGE1 infusions (1989) J Rheumatol, 16, pp. 1433-1435 | |
dc.description | Marasini, B., Massarotti, M., Bottasso, B., Coppola, R., Papa, N.D., Maglione, W., Comparison between iloprost and alprostadil in the treatment of Raynaud's phenomenon (2004) Scand J Rheumatol, 33, pp. 253-256 | |
dc.description | Matucci-Cerinic, M., Denton, C.P., Furst, D.E., Mayes, M.D., Hsu, V.M., Carpentier, P., Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial (2011) Ann Rheum Dis, 70, pp. 32-38 | |
dc.description | Korn, J.H., Mayes, M., Matucci Cerinic, M., Rainisio, M., Pope, J., Hachulla, E., Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist (2004) Arthritis Rheum, 50, pp. 3985-3993 | |
dc.description | Brueckner, C.S., Becker, M.O., Kroencke, T., Huscher, D., Scherer, H.U., Worm, M., Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study (2010) Ann Rheum Dis, 69, pp. 1475-1478 | |
dc.description | Mercado, U., Arroyo de Anda, R., Avendaño, L., Araiza-Casillas, R., Avendaño-Reyes, M., Metoclopramide response in patients with early diffuse systemic sclerosis.Effects on esophageal motility abnormalities (2005) Clin Exp Rheumatol, 23, pp. 685-688 | |
dc.description | Johnson, D.A., Drane, W.E., Curran, J., Benjamin, S.B., Chobanian, S.J., Karvelis, K., Metoclopramide response in patients with progressive systemic sclerosis. Effect on esophageal and gastric motility abnormalities (1987) Arch Intern Med, 147, pp. 1597-1601 | |
dc.description | Nikou, G.C., Toumpanakis, C., Katsiari, C., Charalambopoulos, D., Sfikakis, P.P., Treatment of small intestinal disease in systemic sclerosis with octreotide: a prospective study in seven patients (2007) J Clin Rheumatol, 13, pp. 119-123 | |
dc.description | Verne, G.N., Eaker, E.Y., Hardy, E., Sninsky, C.A., Effect of octreotide and erythromycin on idiopathic and scleroderma-associated intestinal pseudoobstruction (1995) Dig Dis Sci, 40, pp. 1892-1901 | |
dc.description | Marie, I., Dominique, S., Levesque, H., Ducrotté, P., Denis, P., Hellot, M.F., Esophageal involvement and pulmonary manifestations in systemic sclerosis (2001) Arthritis Rheum, 45, pp. 346-354 | |
dc.description | Janiak, P., Thumshirn, M., Menne, D., Fox, M., Halim, S., Fried, M., Clinical trial: the effects of adding ranitidine at night to twice daily omeprazole therapy on nocturnal acid breakthrough and acid reflux in patients with systemic sclerosis-a randomized controlled, cross-over trial (2007) Aliment Pharmacol Ther, 26, pp. 1259-1265 | |
dc.description | Shoenut, J.P., Wieler, J.A., Micflikier, A.B., The extent and pattern of gastro-oesophageal reflux in patients with scleroderma oesophagus: the effect of low-dose omeprazole (1993) Aliment Pharmacol Ther, 7, pp. 509-513 | |
dc.description | Pakozdi, A., Wilson, H., Black, C.M., Denton, C.P., Does long term therapy with lansoprazole slow progression of oesophageal involvement in systemic sclerosis? (2009) Clin Exp Rheumatol, 27 (3 SUPPL. 54), pp. 5-8 | |
dc.description | Wipff, J., Coriat, R., Masciocchi, M., Caramaschi, P., Derk, C.T., Hachulla, E., Outcomes of Barrett's oesophagus related to systemic sclerosis: a 3-year EULAR Scleroderma Trials and Research prospective follow-up study (2011) Rheumatology (Oxford), 50, pp. 1440-1444 | |
dc.description | Kent, M.S., Luketich, J.D., Irshad, K., Awais, O., Alvelo-Rivera, M., Churilla, P., Comparison of surgical approaches to recalcitrant gastroesophageal reflux disease in the patient with scleroderma (2007) Ann Thorac Surg, 84, pp. 1710-1715 | |
dc.description | Lundberg, A.C., Akesson, A., Akesson, B., Dietary intake and nutritional status in patients with systemic sclerosis (1992) Ann Rheum Dis, 51, pp. 1143-1148 | |
dc.description | Baron, M., Hudson, M., Steele, R., Malnutrition is common in systemic sclerosis: results from the Canadian scleroderma research group database (2009) J Rheumatol, 36, pp. 2737-2743. , Canadian Scleroderma Research Group | |
dc.description | Cliff, I.S., Herber, R., Demis, D.J., Control of malabsorption in scleroderma (1966) J Invest Dermatol, 47, pp. 475-483 | |
dc.description | Alpert, L.I., Warner, R.R., Systemic sclerosis: case presenting with tetracycline-responsive malabsorption syndrome (1968) Am J Med, 45, pp. 468-473 | |
dc.description | Brown, M., Teubner, A., Shaffer, J., Herrick, A.L., Home parenteral nutrition-an effective and safe long-term therapy for systemic sclerosis-related intestinal failure (2008) Rheumatology (Oxford), 47, pp. 176-179 | |
dc.description | Parodi, A., Sessarego, M., Greco, A., Bazzica, M., Filaci, G., Setti, M., Small intestinal bacterial overgrowth in patients suffering from scleroderma: clinical effectiveness of its eradication (2008) Am J Gastroenterol, 103, pp. 1257-1262 | |
dc.description | Schnabel, A., Reuter, M., Gross, W.L., Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases (1998) Arthritis Rheum, 41, pp. 1215-1220 | |
dc.description | Yiannopoulos, G., Pastromas, V., Antonopoulos, I., Katsiberis, G., Kalliolias, G., Liossis, S.N., Combination of intravenous pulses of cyclophosphamide and methylprednizolone in patients with systemic sclerosis and interstitial lung disease (2007) Rheumatol Int, 27, pp. 357-361 | |
dc.description | Domiciano, D.S., Bonfá, E., Borges, C.T., Kairalla, R.A., Capelozzi, V.L., Parra, E., A long-term prospective randomized controlled study of non-specific interstitial pneumonia (NSIP) treatment in scleroderma (2011) Clin Rheumatol, 30, pp. 223-229 | |
dc.description | Nannini, C., West, C.P., Erwin, P.J., Matteson, E.L., Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies (2008) Arthritis Res Ther, 10, pp. R124 | |
dc.description | Tochimoto, A., Kawaguchi, Y., Hara, M., Tateishi, M., Fukasawa, C., Takagi, K., Efficacy and safety of intravenous cyclophosphamide pulse therapy with oral prednisolone in the treatment of interstitial lung disease with systemic sclerosis: 4-year follow-up (2011) Mod Rheumatol, 21, pp. 296-301 | |
dc.description | Seibold, J.R., Denton, C.P., Furst, D.E., Guillevin, L., Rubin, L.J., Wells, A., Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis (2010) Arthritis Rheum, 62, pp. 2101-2108 | |
dc.description | Nithyanova, S.I., Brough, G.M., Black, C.M., Denton, C.P., Mycophenolate mofetil in diffuse cutaneous systemioc sclerosis-a retrospective analysis (2007) Rheumatology (Oxford), 46, pp. 442-445 | |
dc.description | Avouac, J., Airò, P., Meune, C., Beretta, L., Dieude, P., Caramaschi, P., Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies (2010) J Rheumatol, 37 (11), pp. 2290-2298. , PMID: 20810505 | |
dc.description | Galiè, N., Hoeper, M.M., Humbert, M., Torbicki, A., Vachiery, J.L., Barbera, J.A., Guidelines for the diagnosis and treatment of pulmonary hypertension (2009) Eur Heart J, 30 (20), pp. 2493-2537 | |
dc.description | Badesch, D.B., Tapson, V.F., McGoon, M.D., Brundage, B.H., Rubin, L.J., Wigley, F.M., Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial (2000) Ann Intern Med, 132, pp. 425-434 | |
dc.description | Caravita, S., Wu, S.C., Secchi, M.B., Dadone, B., Bencini, C., Pierini, S., Long-term effects of intermittent Iloprost infusion on pulmonary arterial pressure in connective tissue disease (2011) Eur J Int Med, 22, pp. 518-521 | |
dc.description | Channick, R.N., Simonneau, G., Sitbon, O., Robbins, I.M., Frost, A., Tapson, V.F., Effects of the dual endothelinreceptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study (2001) Lancet, 358, pp. 1119-1123 | |
dc.description | Rubin, L.J., Badesch, D.B., Barst, R.J., Galie, N., Black, C.M., Keogh, A., Bosentan therapy for pulmonary arterial hypertension (2002) N Engl J Med, 346, pp. 896-903 | |
dc.description | Galiè, N., Olschewski, H., Oudiz, R.J., Torres, F., Frost, A., Ghofrani, H.A., Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2 (2008) Circulation, 117, pp. 3010-3019 | |
dc.description | Saggar, R., Khanna, D., Shapiro, S., Furst, D.E., Maranian, P., Clements, P., Effect of ambrisentan treatment on exercise-induced pulmonary hypertension in systemic sclerosis: A prospective single-center, open-label pilot study (2012) Arthritis Rheum, 64, pp. 4072-4077 | |
dc.description | Galiè, N., Ghofrani, H.A., Torbicki, A., Barst, R.J., Rubin, L.J., Badesch, D., Sildenafil citrate therapy for pulmonary arterial hypertension (2005) N Engl J Med, 353, pp. 2148-2157 | |
dc.description | Badesch, D.B., Hill, N.S., Burgess, G., Rubin, L.J., Barst, R.J., Galiè, N., Sildenafil for pulmonary arterial hypertension associated with connective tissue disease (2007) J Rheumatol, 34, pp. 2417-2422 | |
dc.description | Galiè, N., Brundage, B.H., Ghofrani, H.A., Oudiz, R.J., Simonneau, G., Safdar, Z., Tadalafil therapy for pulmonary arterial hypertension (2009) Circulation, 119, pp. 2894-2903 | |
dc.description | DeMarco, P.J., Weisman, M.H., Seibold, J.R., Furst, D.E., Wong, W.K., Hurwitz, E.L., Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial (2002) Arthritis Rheum, 46, pp. 2983-2989 | |
dc.description | Walker, J.G., Ahern, M.J., Smith, M.D., Coleman, M., Pile, K., Rischmueller, M., Scleroderma renal crisis: poor outcome despite aggressive antihypertensive treatment (2003) Intern Med J, 33, pp. 216-220 | |
dc.description | Penn, H., Howie, A.J., Kingdon, E.J., Bunn, C.C., Stratton, R.J., Black, C.M., Scleroderma renal crisis: patient characteristics and long-term outcomes (2007) QJM, 100, pp. 485-494 | |
dc.description | Teixeira, L., Mouthon, L., Mahr, A., Berezné, A., Agard, C., Mehrenberger, M., Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients (2008) Ann Rheum Dis, 67, pp. 110-116 | |
dc.description | Hudson, M., Baron, M., Lo, E., Weinfeld, J., Furst, D.E., Khanna, D., An international, web-based, prospective cohort study to determine whether the use of ACE inhibitors prior to the onset of scleroderma renal crisis is associated with worse outcomes-methodology and preliminary results (2010) Int J Rheumatol, 2010, p. 347402. , doi:10.1155/2010/347402. Epub 2010 Sep 14 | |
dc.description | Hesselstrand, R., Scheja, A., Wuttge, D., Scleroderma renal crisis in a Swedish systemic sclerosis cohort: survival, renal outcome, and RNA polymerase III antibodies as a risk factor (2012) Scand J Rheumatol, 41, pp. 39-43 | |
dc.description | Ferri, C., Valentini, G., Cozzi, F., Sebastiani, M., Michelassi, C., La Montagna, G., Systemic Sclerosis Study Group of the Italian Society of Rheumatology (SIR-GSSSc). Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients (2002) Medicine, 81, pp. 139-153 | |
dc.description | Scussel-Lonzetti, L., Joyal, F., Raynauld, J.P., Roussin, A., Rich, E., Goulet, J.R., Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival (2002) Medicine, 81, pp. 154-167 | |
dc.description | Ioannidis, J.P., Vlachoyiannopoulos, P.G., Haidich, A.B., Medsger Jr., T.A., Lucas, M., Michet, C.J., Mortality in systemic sclerosis: an international meta-analysis of individual patient data (2005) Am J Med, 118, pp. 2-10 | |
dc.description | Sampaio-Barros, P.D., Bortoluzzo, A.B., Marangoni, R.G., Rocha, L.F., Del Rio, A.P., Samara, A.M., Survival, causes of death, and prognostic factors in systemic sclerosis: analysis of 947 Brazilian patients (2012) J Rheumatol, 39, pp. 1971-1978 | |
dc.description | Montisci, R., Vacca, A., Garau, P., Colonna, P., Ruscazio, M., Passiu, G., Detection of early impairment of coronary flow reserve in patients with systemic sclerosis (2003) Ann Rheum Dis, 62, pp. 890-893 | |
dc.description | Sulli, A., Ghio, M., Bezante, G.P., Deferrari, L., Craviotto, C., Sebastiani, V., Blunted coronary flow reserve in systemic sclerosis (2004) Rheumatology (Oxford), 43 (4), pp. 505-509 | |
dc.description | Kahan, A., Allanore, Y., Primary myocardial involvement in systemic sclerosis (2006) Rheumatology (Oxford), 45 (SUPPL. 4), pp. iv14-7 | |
dc.description | Ishida, R., Murata, Y., Sawada, Y., Nishioka, K., Shibuya, H., Thallium-201 myocardial SPET in patients with collagen disease (2000) Nucl Med Commun, 21, pp. 729-734 | |
dc.description | Akram, M.R., Handler, C.E., Williams, M., Carulli, M.T., Andron, M., Black, C.M., Angiographically proven coronary artery disease in scleroderma (2006) Rheumatology (Oxford), 45, pp. 1395-1398 | |
dc.description | Kahan, A., Devaux, J.Y., Amor, B., Menkes, C.J., Weber, S., Foult, J.M., Pharmacodynamic effect of dipyridamole on thallium-201 myocardial perfusion in progressive systemic sclerosis with diffuse scleroderma (1986) Ann Rheum Dis, 45, pp. 718-725 | |
dc.description | Kahan, A., Devaux, J.Y., Amor, B., Menkès, C.J., Weber, S., Nitenberg, A., Nifedipine and thallium-201 myocardial perfusion in progressive systemic sclerosis (1986) N Engl J Med, 314, pp. 1397-1402 | |
dc.description | Kahan, A., Devaux, J.Y., Amor, B., Menkes, C.J., Weber, S., Venot, A., Nicardipine improves myocardial perfusion in systemic sclerosis (1988) J Rheumatol, 15, pp. 1395-1400 | |
dc.description | Kahan, A., Devaux, J.Y., Amor, B., Menkès, C.J., Weber, S., Venot, A., The effect of captopril on thallium 201 myocardial perfusion in systemic sclerosis (1990) Clin Pharmacol Ther, 47, pp. 483-489 | |
dc.description | Duboc, D., Kahan, A., Maziere, B., Loc'h, C., Crouzel, C., Menkès, C.J., The effect of nifedipine on myocardial perfusion and metabolism in systemic sclerosis. A positron emission tomographic study (1991) Arthritis Rheum, 34, pp. 198-203 | |
dc.description | Vignaux, O., Allanore, Y., Meune, C., Pascal, O., Duboc, D., Weber, S., Evaluation of the effect of nifedipine upon myocardial perfusion and contractility using cardiac magnetic resonance imaging and tissue Doppler echocardiography in systemic sclerosis (2005) Ann Rheum Dis, 64, pp. 1268-1273 | |
dc.description | Kahan, A., Devaux, J.Y., Amor, B., Menkès, C.J., Weber, S., Guérin, F., Pharmacodynamic effect of nicardipine on left ventricular function in systemic sclerosis (1990) J Cardiovasc Pharmacol, 15, pp. 249-253 | |
dc.description | Hegedüs, I., Czirják, L., Left ventricular wall thickness and disease duration in systemic sclerosis (1993) Postgrad Med J, 69, pp. 285-290 | |
dc.description | Meune, C., Allanore, Y., Pascal, O., Devaux, J.Y., Dessault, O., Duboc, D., Myocardial contractility is early affected in systemic sclerosis: a tissue Doppler echocardiography study (2005) Eur J Echocardiogr, 6, pp. 351-357 | |
dc.description | Meune, C., Avouac, J., Wahbi, K., Cabanes, L., Wipff, J., Mouthon, L., Cardiac involvement in systemic sclerosis assessed by tissue-doppler echocardiography during routine care: A controlled study of 100 consecutive patients (2008) Arthritis Rheum, 58, pp. 1803-1809 | |
dc.description | Meune, C., Allanore, Y., Devaux, J.Y., Dessault, O., Duboc, D., Weber, S., High prevalence of right ventricular systolic dysfunction in early systemic sclerosis (2004) J Rheumatol, 31, pp. 1941-1945 | |
dc.description | Bernardo, P., Conforti, M.L., Bellando-Randone, S., Pieragnoli, P., Blagojevic, J., Kaloudi, O., Implantable | |
dc.publisher | | |
dc.relation | Revista Brasileira de Reumatologia | |
dc.rights | fechado | |
dc.source | Scopus | |
dc.title | Recommendations For The Management And Treatment Of Systemic Sclerosis [recomendações Sobre Diagnóstico E Tratamento Da Esclerose Sistêmica] | |
dc.type | Artículos de revistas | |